中国药物科学预印本平台

简要指南

CONTENTS目录

第一章 平台说明

一、什么是预印本？

预印本（**Preprint**）是一种用于在科研团体间进行学术交流的论文手稿，这样的论文手稿在开放交流之前未经同行评审。

二、什么是预印本学术交流平台？

预印本学术交流平台是接收科研团体提交预印本论文手稿并为这些论文手稿提供开放交流服务的平台系统。

三、什么是中国药物科学预印本平台（ChinaXiv-Pharmaceutical Science）？

中国药物科学预印本平台，即中国药物科学预印本学术交流平台，由中国科学院上海药物研究所与 ChinaXiv 共建，并按照国际通行模式规范运营，是一种新型的学界自治的科技成果交流与共享平台，提供英文科技论文和会议论文的预印本存储发布与开放获取及学术交流服务，与传统的期刊成果发布方式形成有效互补，鼓励科研人员公平竞争，保证优秀科研成果首发权认定，推动科研成果的开放获取，促进更大范围的学术交流，支持中国药物科学发展。

四、发布预印本对论文作者有哪些益处？

- 权威的首发权确认和证明
- 听取同行的评议，为进一步正式发表打下基础
- 让成果尽早被引用
- 帮助实现成果的积累
- 提供成果交流渠道，扩大成果交流范围
- 回归学术交流的本质，加速药物科学学术交流
- 为更多阴性结果和非主流观点的发布提供可能

五、发布预印本对论文机构有哪些益处？

- 保护机构成果
- 促进学术交流与合作
- 提高机构影响力

第二章 论文提交步骤

1、进入平台首页，网址：https://phar.chinaxiv.org/。点击【Submit】按钮，进入投稿流程。

2、直接输入中国科技云账号和密码点击登录。中国科技云账号和密码即药物所（simm.ac.cn 或 cdser.simm.ac.cn）机构邮箱和邮箱密码。如无中国科技云账号，请点击下方【Reg】，注册账号。说明：尽量使用 ac.cn 或 edu.cn 结尾的邮箱注册账号，不需要进行作者身份认证。

3、登录进来后可以点击【Single submit】按钮直接提交论文。如果您此前已经在 arXiv 提交过预印本论文，可直接点击【Arxiv submit】，输入之前提交在 arXiv 上的 arXiv ID 号可一键提交。

4、请核实个人机构、邮箱等信息，按个人实际情况选择版权声明、CC 许可类型，阅读许可信息，并勾选同意上述政策声明复选框后，点击【Next】。说明：CC 许可类型建议选择 CC BY-NC-SA 4.0。

Confirm User Information	2. Promise	3. Upload File	4. Format Checks	5. Description Info	6. Preview

Step 1: read the following license agreement

Please certify user information

*Name		*Institution	中国科学院上海药物研究所
*Email		ORCID	
*Address	上海市张江祖冲之路555号	User Information: ◉Chinese ○English

We must have current contact information, especially your email address. Verify your name and institutional affiliation。Return to the registration form to update your information，your e-mail address is your user name，once registration is successful, no modifications will be allowed。

📖
•Thesis template&Downloads

Copyright Pledge

○ Submitted as the author of this article and promised to have the right to upload this article.
○ As the author of this article, he has not submitted it to the publishing house and promised to have the right to upload this article.
○ Submitted as the author of this article, and promised to obtain the permission from the publisher to submit the paper to the pre-release platform.
○ Submitted as the authorized agent of the author of this article.

License Information

Before your article is submitted, you must select a license or statement and give us the right to distribute your articles （"The specific information of each license can be accessed in the "License Discussion Area". If you do not know the license information, it is recommended that you select the first item, which is the most traditional and common mode of authorization"）。

○ ChinaXiv.org perpetual, non-exclusive license to distribute this article (Minimal rights required by ChinaXiv.org. Select this unless you understand the implications of other licenses.)
○ Creative Commons Attribution license (CC BY 4.0)
○ Creative Commons Attribution-ShareAlike license (CC BY-SA 4.0)
○ Creative Commons Attribution-Noncommercial-ShareAlike license (CC BY-NC-SA 4.0)
○ Creative Commons Public Domain Dedication (CC0 1.0)

Policy Statement:

1.I understand that submissions cannot be completely removed once accepted.

2.I understand that ChinaXiv.org reserves the right to reclassify or reject any submission.

3.If the article I submit violates the relevant laws or infringes the copyright of others, the pre-release platform of Chinese scientific and technological papers has the right to delete it.

4.I understand that my submission will be automatically compared with other ChinaXiv articles, and detected text overlap may be noted.

License Information

ChinaXiv does not ask that copyright be transferred. However, we require sufficient rights to allow us to distribute submitted articles in perpetuity.

In order to submit an article to ChinaXiv, the submitter must either:

• grant ChinaXiv a non-exclusive and irrevocable license to distribute the article, and certify that he/she has the right to grant this license;

• certify that the work is available under one of the following Creative Commons licenses and that he/she has the right to assign this license:

☐ I agree to "ChinaXiv paper license agreement" the above policies。

Next

5、阅读 ChinaXiv 论文提交与评审基本准则，并勾选同意复选框后点击【Next】。

Confirm User Information	2. Promise	3. Upload File	4. Format Checks	5. Description Info	6. Preview

Step2:submitter commitment(Attention should be paid to avoid conflicts between the platform and the agreements of other journals. Any responsibility arising therefrom should be borne by the submitter, which has nothing to do with the platform)

ChinaXiv Paper Submitter Integrity Commitment

Basic Guidelines for ChinaXiv Paper Submitters and Reviewers

Chapter 1 General Provisions

1 In order to maintain a good academic atmosphere, protect the intellectual property rights of authors, strengthen academic supervision, and promote academic exchanges, in accordance with the "Copyright Law of the People's Republic of China", "Patent Law of the People's Republic of China", "State Secrecy Law of the People's Republic of China", "Internet Security Law of the People's Republic of China", "Regulations on the Protection of the Right to Disseminate Information Networks", "Regulations on the Protection of Computer Software", "Regulations for the Implementation of the Copyright Law" and other relevant laws and regulations, formulate these guidelines.

2 These guidelines apply to paper submitters and paper reviewers who participate in and use the services provided by the Chinese Academy of Sciences' scientific paper pre-publishing platform (hereinafter referred to as ChinaXiv).

3 Users should adhere to the scientific spirit of seeking truth from facts and a serious scientific attitude, strictly abide by the academic ethics recognized at home and abroad, respect the intellectual property rights of others, and abide by relevant national laws and regulations.

☐ I have read the 《Basic Guidelines for ChinaXiv Paper Submitters and Paper Reviewers》, and solemnly promise to strictly abide by the national laws and regulations and the following guidelines. If there is any violation, I shall bear the corresponding legal responsibility and agree to the handling measures of ChinaXiv.

[Next] [Return]

6、选择预印本论文类型（通常选择 Academic Papers）后，点击【Browse】选择稿件后点击【Upload】即为上传稿件。说明：平台支持的文献类型包括：PDF、Office Word、WPS Office、Latex。

Confirm User Information	2. Promise	3. Upload File	4. Format Checks	5. Description Info	6. Preview

step3:Your submission to the archive must be in one of the following formats (listed in order of preference):

Paper format regulation

* Format1:Adobe PDF
* Format2:Office Word
* Format31:WPS Office
* Format4:Latex(TEX、DVI and PS，Recommend DVI and PS)
Note:
(1)To ensure normal audits，Please you adhere to the above document format;
(2)New uploaded papers will automatically overwrite previous ones and we take the latest upload papers as the standard。
Add files

Preprint Type Academic Papers

* Browse   Upload

Upload research identification materials

When submitting the manuscript, submitting the "Research Identification Materials of the Responsible Person (Thesis Author)" will help the platform to quickly identify your research identity and disclose your submitted manuscript in a timely manner.**Download**.
Browse   Upload

点击 **Upload** 后可查看提交的论文版本。如有论文相关音视频或图表、实验数据等，请按照实际情况选择上传。

Preprint Type Academic Papers

* Browse   Replace

* the paper of latest version: 202402.00142v1 (1).pdf   查看

Upload research identification materials

When submitting the manuscript, submitting the "Research Identification Materials of the Responsible Person (Thesis Author)" will help the platform to quickly identify your research identity and disclose your submitted manuscript in a timely manner.**Download**。

Browse   Upload

Upload the relevant audio and video files of the paper(rar、zip)

Browse   Upload

Science Data Bank
科学数据银行

Upload files such as graphs, experimental data, etc.(rar、zip)

Browse   Upload

Next

如需替换稿件，可以点击上图的【**Replace**】按钮，重新上传稿件。

7、点击【Next】提示格式审查，直接点击【Next】即可。

Confirm User Information ≫   2. Promise ≫   3. Upload File ≫   4. Format Checks ≫   5. Description Info ≫   6. Preview ≫

Step3:Format check，check the format of the paper

Format check

Click and Read the PDF

The article is checked successfully. Please proceed to the next step;

Can be verified by third-party paper grammar detection tools: 火龙果写作 Third Party Tools (Test)

Third party editing and polishing service tools: Springer Nature 旗下专业编辑润色服务品牌 AJE

Return   Next

8、填写论文题名、作者、摘要、关键词等信息，学科分类请选择【**Pharmaceutical Science**】，再选择具体学科方向（如 **Structural Biology**）。说明：作者信息中的 **Institution** 写下方机构对应的序号。点击 ⊕ 可以增加作者和机构。

Confirm User Information ≫	2. Promise ≫	3. Upload File ≫	4. Format Checks ≫	5. Description Info ≫	6. Preview ≫

Step4:Please fill in the paper's description information as requested......

Paper description information

* Language: [英文]

* English Title: [   ]

Author Info: * English: [   ]   * Institution: [   ]   * Email: [   ]   □ Correspondent ⊕ ⊖

Note: (1) For author of English paper, please follow "Lastname", "Firstname", For example "Wang, Haiying", "Gates, Bill".
(2) The authors added or deleted, please use the "+/-".
(3) Please select the corresponding organization serial number, multiple institutional numbers are separated by commas in English, e.g. "1,2".

Author institution: 1. *English：[   ]   ⊕ ⊖

(Add author organization, please click "+", Delete, please click "-")

* English Abstract: [   ]

* English keywords: [   ]

Fund project number: [   ]   Project name: [   ]

Subject label: [   ]

Report number: [   ]

* Classification: [Pharmaceutical Science] [Structural Biology] [Add Class]

[Save]   [Next]

9、 再次确认论文信息后，点击选择稿件的同行评议状态。点击【Submit】即完成投稿。

English
keywords: drug discovery;EGFR;structure-activity
Classification: Pharmaceutical Science 》 Structural Biology;
Full Text: Browse

The revision content when the submitted paper version is updated, the status associated with journal papers and conference papers, such as the status of the manuscript submitted for review, etc.

*
Contribution:
description:

Save		Submit	Back to previous step

如已在期刊出版，请选择 **Published**，并填写期刊名称、卷期页面、**DOI** 号等。

*
Contribution: Published
description:

Journal
Title:

volume: issue:

ISSN: 页码:

Journal link:

DOI:

引用方式:

Save	Submit	Back to previous step

如已投稿并被期刊接收，可选择 **Accepted**，并填写具体期刊名称和 **ISSN** 号。

如已投稿但仍无结果，可选择 **Under Review** 或 **Journal Submitted**。 如未向任何期刊、会议投稿，请选择 **No Submitted**。

10、投稿后，平台管理人员会立即进行简单审查，审查通过后会保证在投稿当天或 **1~2** 个工作日内发布您的稿件。

11、预印本需要更新版本或后续已在期刊出版需更新出版状态，您可以点击【My Center】下的【My Papers】，点击需要更新的那条预印本记录中的【Update】。后续步骤与投稿步骤一致。

说明：更新版本后，预印本记录会出现两个版本，点击【View This Version】可切换查看另一版本内容，论文的提交时间、出版状态等也跟随展示在不同版本中。

Version History			
[V2]	2024-04-17 13:49:48	ChinaXiv:202311.00051V2	Download
[V1]	2023-11-03 21:26:11	ChinaXiv:202311.00051v1 View This Version	Download

点击平台首页【Browse】或【more+】可查阅、下载本平台已发布的预印本。

第三章 常见问题（FAQs）

1、ChinaXiv-Pharmaceutical Science 欢迎什么样的研究论文？

我们欢迎药物科学领域的基础理论研究和实验研究。不接收虚构类作品、新闻报道、科普文章、产品广告、教学素材、政策声明、方法说明和简单陈述的实验步骤。

2、ChinaXiv-Pharmaceutical Science 预印本经过同行评议吗？

提交的论文目前不会被同行评议、编辑与排版。但所有论文都会经过审核，以避免与药物科学研究无关的内容，或含有不法、危险等信息，并会对内容进行反剽窃检查。

3、投稿到 ChinaXiv-Pharmaceutical Science 需要付费吗？

提交论文到 ChinaXiv-Pharmaceutical Science 无需付费，下载预印本也无需付费。

4、谁具有 ChinaXiv-Pharmaceutical Science 预印本的版权?

作者仍然具有预印本论文的版权,并且能够向期刊投稿。**ChinaXiv-Pharmaceutical Science** 鼓励作者将预印本论文投递至传统期刊发表。

5、期刊会认为我一稿多投吗?

基本上大部分学术期刊均接收已经在预印本平台公开过的稿件。作者投稿预印本之前,需要去期刊官网查询了解具体的预印本政策。

6、ChinaXiv-Pharmaceutical Science 有语言要求吗?

英文。

7、提交论文到ChinaXiv-Pharmaceutical Science后,多长时间可以上线公开?

审核通过后,一般在投稿当天或之后的 **1~2** 个工作日就可以在平台上查看到论文。

8、ChinaXiv-Pharmaceutical Science 具有影响因子吗?

没有,**ChinaXiv-Pharmaceutical Science** 不是期刊,没有影响因子。

9、发表在 ChinaXiv-Pharmaceutical Science 上的论文可以被引用吗?

可以,**ChinaXiv-Pharmaceutical Science** 为每篇论文均提供了引用方式。以下样式供参考:

Hongmin Cai, Shimeng Guo, Youwei Xu, Zhikan Xia, Junrui Li, Jun Sun, Yi Jiang, Xin Xie, H. Eric Xu. (2023). Cryo-EM structures of adenosine receptor A3AR bound to selective agonists. doi:10.12074/202311.00051V1.
当预印本论文已被学术期刊接收出版后，建议引用期刊来源。

10、我能将已发布在预印本系统中的论文撤回或移除吗？

不能，**ChinaXiv-Pharmaceutical Science** 上的手稿具有唯一标示符 **DOI**，是可以被引用的，并构成了一种科学记录。手稿可以被谷歌和百度学术索引，并且形成独立于 **ChinaXiv-Pharmaceutical Science** 的独立数字实体。因此，**ChinaXiv-Pharmaceutical Science** 不支持撤回和移除论文。您可以上传更新后的版本，我们会重新审核发布，同时，原始论文仍可以访问。除非由于法律原因，论文才会被移除。

11、如何纠正预印本中的错误？

直接提交您的修订版即可。**ChinaXiv-Pharmaceutical Science** 具有版本管理功能，修订版本与以前版本会相互关联，形成该成果逐渐完善的记录和追踪。

12、如何联系 ChinaXiv-Pharmaceutical Science?

邮箱：**xkzx@simm.ac.cn**
电话：**021-68077923**

第四章 药物科学领域重点期刊预印本政策

经调研，药物科学领域发文较多的期刊都允许在投稿前发布预印本，但部分期刊提出需遵守出版商的要求。各期刊政策内容及具体要求见"附件 1: 药物科学领域重点期刊预印本政策"（微信扫码查看）。

第五章 中国药物科学预印本平台投稿须知

1、征稿范围包括药物科学及其相关领域的理论研究和实验研究。来稿需逻辑清晰、论点明确、数据可靠、图文清晰简明、字体格式规范。

2、本平台只接收网络投稿（**https://phar.chinaxiv.org/**）。

3、撰稿要求

    3.1 来稿需结构完整。一般包括标题、作者信息、摘要、关键词、正文、参考文献等。

    3.2 首页脚注包括基金项目（如有需注明）和通讯作者信息。

    3.3 正文中标题层次统一使用阿拉伯数字表示，各级之间使用小圆点，最末一级不加点。例如二级标题为"**1.1**"，三级标题为"**1.1.1**"。

    3.4 正文内容包括前言、方法、结果、讨论等。

4、相同内容、多名作者的稿件上传一次即可。

5、预印本一旦发表之后除非法律问题，不可撤销。